Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Micreos logo — Micreos is a biotech company focused on discovering and deve...

Micreos

Micreos is a biotech company focused on discovering and developing recombinant technology

Founded 2022 Switzerland Baar, Switzerland 21 employees Venture round Total: $59.50M Biotechnology, Design +1

General Information

Company Name Micreos
Founded Year 2022
Location Switzerland Baar, Switzerland
Founders / Decision Makers
Team member
Employees 21
Industries Biotechnology, Design, Health Care
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Micreos . To contact Micreos , visit micreos.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Micreos compare?

A PDF of Micreos and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Micreos soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Micreos

Micreos is a platform biotech company founded in 2006, with its headquarters in Switzerland. The company focuses on discovering and developing recombinant proteins for chronic Dermatology and Oncology conditions. Micreos is making strides in clinical-stage pharmaceutical biotech, with a vision to positively impact patient care and address global health care systems' concerns about antimicrobial resistance (AMR). Micreos' unique capability in modular engineering to optimize enzyme therapeutics has led to the development of three endolysin-based investigational antimicrobials. These antimicrobials target the detrimental impact of Staphylococcus aureus (S. aureus) in oncology, dermatology, and bloodstream infections. The company's mission is to combat harmful bacteria in an era of antimicrobial resistance. Micreos recently secured a significant €25.00M Venture Round investment on 25 October 2022. Micreos' innovative approach to selectively killing only harmful bacteria while preserving the health-enhancing microbiome sets it apart in the biotechnology and healthcare industries. The company's commitment to developing medicinal solutions and forging partnerships across medicine demonstrates its potential to drive meaningful change in the fight against antimicrobial resistance. Overall, Micreos stands at the forefront of biotech innovation, poised to make a significant impact in improving patient outcomes and global healthcare systems.

Business keywords: biotech company, recombinant proteins, clinical-stage pharmaceutical, antimicrobial resistance, endolysin-based investigational antimicrobials, dermatology, oncology, antibiotic resistance, enzyme therapeutics, microbiome preservation, FDA-approved products, pharmaceutical development, data-driven healthcare solutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round €25.00M -
25 Oct 2022
Venture Round €32.00M -
30 Sep 2021
Grant €2.50M 1
Horizon 2020
12 Nov 2019
Venture Round Undisclosed -
23 May 2012

Micreos Alternatives & Competitors

View All Alternatives
Micreos vs
PolyPid Ltd.
PolyPid Ltd. Israel

Controlled, extended-release, local delivery of medication at effective release rates over predeterm...

Post-IPO Equity
66 employees
Biopharma, Biotechnology
Compare Micreos vs PolyPid Ltd.
Micreos vs
Adaptive Phage Therapeutics
Adaptive Phage Therapeutics United States

To save lives or restore health as a leader in safe, rapidly deployable, cost-effective cures for ba...

Acquired
28 employees
Biotechnology, Health Care
Micreos vs
Marina Biotech, Inc.
Marina Biotech, Inc. United States

Marina Biotech’s focus is to treat the intersection of arthritis, pain, hypertension, and oncology d...

Post-IPO Equity
11 employees
Biotechnology, Health Care
View all alternatives

FAQ About Micreos

Micreos is a biotech company focused on discovering and developing recombinant technology
Micreos was founded in 2022.
Micreos is headquartered in Baar, Switzerland.
Micreos operates in Biotechnology, Design and Health Care. Its work centres on biotech company, recombinant proteins, clinical-stage pharmaceutical and antimicrobial resistance.
Micreos has approximately 21 employees.
Micreos has completed 4 funding rounds, raising a total of $59.50M. The latest funding stage is Venture round.
Top alternatives and competitors to Micreos include PolyPid Ltd. , Adaptive Phage Therapeutics, Marina Biotech, Inc., Notable, Prosensa. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Micreos and PolyPid Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Micreos , https://bouncewatch.com/company/micreos, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes